1. To improve patients'knowledge about their medication through structured drug counseling by the health care professionals in the hospital. 2. To improve the use of medicines by patients during their stay in hospital and after discharge.Study…
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
longziekten en kanker
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
1. difference in knowledge about prescribed medicines between intervention and
control group at measurement II, per patient corrected for the basis at
measurement I (method: questionnaires);
2. differences in correct use of medicines between intervention and control
group at measurement III (method: questionnaires).
Secondary outcome
1. differences in reporting medication deviations retrospectively at the time
of discharge from hospital between intervention and control group (measurement
II)
2. differences in satisfaction about the received information about medicines
(measurement II).
Background summary
n.v.t.
Study objective
1. To improve patients'knowledge about their medication through structured drug
counseling by the health care professionals in the hospital.
2. To improve the use of medicines by patients during their stay in hospital
and after discharge.
Study design: pre and post test design
Study design
3 measurements at the departments of lung diseases and oncology during the
intervention period as well as control period. Measurement I: 1-3 days after
admission. Measurement II: during discharge. Measurement III: during
re-admission or control visit.
Intervention
1. structured information about medicines; individual medication chart during
admission and discharge, brochures about specific medicines;
2. patient safety chart with tips for the correct use of medicines.
The intervention measurements at the departments of lung diseases and oncology
lasts 2 months. The control measeruments lasts 2 months (same departments).
Study burden and risks
Burden associated with participation:
15 minutes per questionnaire; 3 questionnaires at different moments; 45 minutes
in total.
There are no risks to be expected with participation.
De Boelelaan 1117
1081 HV Amsterdam
Nederland
De Boelelaan 1117
1081 HV Amsterdam
Nederland
Listed location countries
Age
Inclusion criteria
1. admission at one of the participating departments;
2. informed consent;
3. duration of admission at least 3 days maximally a month;
Exclusion criteria
1. patients younger than 18 years;
2. patients for whom participation in the trial is too great an effort (a health care professional assesses whether a patient is capable to participate)
3. senile dementia, confusion of the patient;
4. inability to express in Dutch language;
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| ISRCTN | ISRCTN04371570 |
| CCMO | NL15456.029.06 |